Supplementary appendix: A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer

dataset

posted on 2024-04-12, 13:24 authored by Himani Aggarwal, Kerigo Ndirangu, Katherine Winfree, Catherine Muehlenbein, Emily Zhu, Vanita Tongbram, Howard Thom

These are peer-reviewed supplementary materials for the article 'A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer' published in the Journal of Comparative Effectiveness Research.

Additional Methodology: 3
Figures: 5
Tables: 7
Inputs: 15
Results: 19
References: 31

Introduction: In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points. Results: Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than docetaxel.